future research projects for bridging these gaps. Diagnosis of ‘malignant’ pheochromocytoma and paraganglioma: state of the science Under the revised WHO classification (2018), pheochromocytomas and paragangliomas (PPGLs) are now referred to as
Search Results
Patricia L M Dahia, Roderick Clifton-Bligh, Anne-Paule Gimenez-Roqueplo, Mercedes Robledo, and Camilo Jimenez
Adrian F Daly, Emilie Castermans, Lindsey Oudijk, Mirtha A Guitelman, Pablo Beckers, Iulia Potorac, Sebastian J C M M Neggers, Nathalie Sacre, Aart-Jan van der Lely, Vincent Bours, Wouter W de Herder, and Albert Beckers
.ENDOEN.2016.10.012 ) Korpershoek E Koffy D Eussen BH Oudijk L Papathomas TG van Nederveen FH Belt EJT Franssen GJH Restuccia DFJ Krol NMG , 2016 Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis
Eamonn R Maher
oxygen-dependent prolyl hydroxylases are inactive, pVHL-dependent degradation of HIFα subunits is compromised and HIF1 and HIF2 are stabilised and activate downstream transcriptional pathways. A notable feature of pheochromocytoma and paraganglioma is the
Jenny Welander, Adam Andreasson, Michael Brauckhoff, Martin Bäckdahl, Catharina Larsson, Oliver Gimm, and Peter Söderkvist
Previously reported in pheochromocytoma/paraganglioma ( Comino-Mendez et al . 2013 , Toledo et al . 2013 ). d Previously reported in pheochromocytoma/paraganglioma ( Lorenzo et al . 2013 ). e Malignant according to AFIP criteria ( Lack 2007 ), local
H J L M Timmers, F M Brouwers, A R M M Hermus, F C G J Sweep, A A J Verhofstad, A L M Verbeek, K Pacak, and J W M Lenders
Introduction Pheochromocytoma (PHEO) is a rare catecholamine producing tumor that derives from chromaffin cells of the adrenal medulla or extra-adrenal abdominal and thoracic paraganglia ( DeLellis et al . 2004 , Lenders et al . 2005 , Pacak et
Jean-Pierre Bayley and Peter Devilee
use in 2D cell culture, PC12 cells have also been used to produce mouse xenografts for a wide variety of purposes, including the study of malignant behavior of pheochromocytomas ( Zielke et al. 1998 ), the efficacy of 131I MIBG targeted radiotherapy
Noriko Kimura, Ryoichi Takayanagi, Nae Takizawa, Eiji Itagaki, Takayuki Katabami, Narihiko Kakoi, Hiromi Rakugi, Yukihiro Ikeda, Akiyo Tanabe, Takeshi Nigawara, Sadayoshi Ito, Itaru Kimura, Mitsuhide Naruse, and The Phaeochromocytoma Study Group in Japan
epinephrine-producing tumours. GAPP is composed of six parameters; those parameters have previously been examined for significance for differentiating between benign and malignant pheochromocytomas. Ki67, which is a marker for proliferating cells, has been of
Noriko Kimura, Kazuhiro Takekoshi, Akira Horii, Ryo Morimoto, Tsuneo Imai, Yutaka Oki, Tomohito Saito, Sanae Midorikawa, Tadashi Arao, Chiho Sugisawa, Masanobu Yamada, Yuichi Otuka, Isao Kurihara, Kokichi Sugano, Minoru Nakane, Atsushi Fukuuchi, Takumi Kitamoto, Jun Saito, Tetsuo Nishikawa, and Mitsuhide Naruse
-Roqueplo AP 2007 Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas . Journal of Clinical Endocrinology and Metabolism 92 3822 – 3828 . ( doi:10.1210/jc.2007-0709 ). Benn DE
Thibault Bahougne, Alessio Imperiale, Gerlinde Averous, Gerard Chabrier, Nelly Burnichon, Anne Paule Gimenez-Roqueplo, Nassim Dali-Youcef, Rossella Libe, Eric Baudin, Catherine Roy, Herve Lang, and Laurence Kessler
Dear Editor, Pheochromocytoma (PHEO) and extra-adrenal paraganglioma (PGL) are neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and the autonomic nervous system, respectively. These neoplasms are malignant in
Karel Pacak and Roderick Clifton-Bligh
WHO Classification of Tumours of Endocrine Organs, including a new definition and terminology of pheochromocytoma and paraganglioma that is now being considered. The initial motion replaced the term ‘malignant’ with the term ‘metastatic’ ( Tischler et
